FBXO44 Regulates FOXP1 Degradation Through AURKA‐Dependent Phosphorylation to Promote Colorectal Cancer Progression
Advanced Science · 2025
DOI: 10.1002/advs.202415458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Hongxu Nie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Nanji…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Forkhead Transcription Factors, F-Box Proteins, Aurora Kinase A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nature Key Research and Development Program of Jiangsu Province, Basic Research Program of Jiangsu Province, Jiangsu Key Medical Discipline.
Abstract (Originalsprache)
Emerging evidence highlights the role of SCF E3 ligases, consisting of SKP1, cullin‐1, and F‐box proteins, in cancer biology by regulating the ubiquitination and degradation of key proteins. This study identifies F‐box only protein 44 (FBXO44) as an oncogene in colorectal cancer (CRC). FBXO44 is upregulated in CRC patients and correlates with poor prognosis. Knockdown of FBXO44 inhibits CRC cell proliferation and organoid growth, as well as xenograft tumor growth and AOM/DSS‐induced intestinal tumorigenesis. Conversely, FBXO44 overexpression accelerates tumor growth in vitro and in vivo. Mechanistically, FBXO44 targets Forkhead box protein P1 (FOXP1) for degradation. Aurora kinase A (AURKA) phosphorylates FOXP1 at Ser440, enhancing FBXO44 binding, leading to K48‐linked ubiquitination at K377 and proteasomal degradation. This degradation relieves FOXP1 repression of Cyclin E2, promoting CRC cell proliferation. In summary, FBXO44 is an oncogene that promotes CRC tumorigenesis by degrading FOXP1 and upregulating Cyclin E2, offering a potential therapeutic target for CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
- Jiangsu Province Engineering Research Center of Colorectal Cancer Precision Medicine and Translational Medicine, Nanjing, 210029, China.
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210029, China.
- Department of General Surgery, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, 213100, China.
- Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, China.
ORCID-Profile: Yueming Sun
Förderung
- Nature Key Research and Development Program of Jiangsu Province
- Basic Research Program of Jiangsu Province
- Jiangsu Key Medical Discipline
- National Natural Science Foundation of China
Zitieren
APA
Nie, H., Xu, H., Yang, S., Tian, C., Wang, T., Jin, C., Chen, Z., Wang, X., Tang, J., Feng, Y., & Sun, Y. (2025). FBXO44 Regulates FOXP1 Degradation Through AURKA‐Dependent Phosphorylation to Promote Colorectal Cancer Progression. Advanced Science. https://doi.org/10.1002/advs.202415458
Vancouver
Nie H, Xu H, Yang S, Tian C, Wang T, Jin C, et al. FBXO44 Regulates FOXP1 Degradation Through AURKA‐Dependent Phosphorylation to Promote Colorectal Cancer Progression. Advanced Science. 2025. doi:10.1002/advs.202415458
BibTeX
@article{Nie2025,
author = {Nie, Hongxu and Xu, Hengjie and Yang, Sheng and Tian, Chuanxin and Wang, Tuo and Jin, Chi and Chen, Zhihao and Wang, Xiaowei and Tang, Junwei and Feng, Yifei and Sun, Yueming},
title = {FBXO44 Regulates FOXP1 Degradation Through AURKA‐Dependent Phosphorylation to Promote Colorectal Cancer Progression},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202415458}
}
EUVIMED